Role of LRP5/6/GSK‐3β/β‐catenin in the differences in exenatide‐ and insulin‐promoted T2D osteogenesis and osteomodulation

Abstract

AbstractBackground and PurposeInsulin and exenatide are two hypoglycaemic agents that exhibit different osteogenic effects. This study compared the differences between exenatide and insulin in osseointegration in a rat model of Type 2 diabetes (T2D) and explored the mechanisms promoting osteogenesis in this model of T2D.Experimental ApproachIn vivo, micro‐CT was used to detect differences in the peri‐implant bone microstructure in vivo. Histology, dual‐fluorescent labelling, immunofluorescence and immunohistochemistry were used to detect differences in tissue, cell and protein expression around the implants. In vitro, RT‐PCR and western blotting were used to measure the expression of osteogenesis‐ and Wnt signalling‐related genes and proteins in bone marrow mesenchymal stromal cells (BMSCs) from rats with T2D (TBMSCs) after PBS, insulin and exenatide treatment. RT‐PCR was used to detect the expression of Wnt bypass cascade reactions under Wnt inactivation.Key ResultsMicro‐CT and section staining showed exenatide extensively promoted peri‐implant osseointegration. Both in vivo and in vitro experiments showed exenatide substantially increased the expression of osteogenesis‐related and activated the LRP5/6/GSK‐3β/β‐catenin‐related Wnt pathway. Furthermore, exenatide suppressed expression of Bmpr1a to inhibit lipogenesis and promoted expression of Btrc to suppress inflammation.Conclusion and ImplicationsCompared to insulin, exenatide significantly improved osteogenesis in T2D rats and TBMSCs. In addition to its dependence on LRP5/6/GSK‐3β/β‐catenin signalling for osteogenic differentiation, exenatide‐mediated osteomodulation also involves inhibition of inflammation and adipogenesis by BMPR1A and β‐TrCP, respectively.